In Japan, the Oncomine Dx Target test Multi CDx System (Thermo Fisher Scientific Inc., Waltham, MA, USA) was approved as a CDx test to identify alterations in five driver genes for first‐line targeted treatments in NSCLC are available: EGFR, ALK, ROS1, BRAF (exon 15 V600E), and RET. This evidence concerns the gene BRAF and non-small cell lung carcinoma.